Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetic Predictors of Response to Keytruda in Advanced NSCLC
NCT02710396Phase 2Terminated
- Sponsor
- Columbia University
- Start
- May 2016
- Primary completion
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Columbia University. Started May 2016; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02710396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02710396.